ADAR1 Capital Management’s Ovid Therapeutics OVID Stock Holding History

ADAR1 Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Buy	4,544,113 +259,113	+6%	+$463K	0.59%	45
2025 Q4	$6.98M	Buy	4,285,000 +4,272,154	+33,257%	+$6.58M	0.51%	43
2025 Q3	$16.7K	Sell	12,846 -103,021	-89%	-$89.3K	﹤0.01%	216
2025 Q2	$38.2K	Hold	115,867	–	–	0.01%	194
2025 Q1	$36.1K	Sell	115,867 -14,665	-11%	-$9.02K	0.01%	184
2024 Q4	$122K	Buy	130,532 +92,789	+246%	+$104K	0.02%	175
2024 Q3	$44.5K	Buy	37,743 +18,553	+97%	+$19.4K	0.01%	221
2024 Q2	$14.8K	Buy	19,190 +2,744	+17%	+$7.64K	﹤0.01%	228
2024 Q1	$50.2K	Buy	16,446 +3,200	+24%	+$10.7K	0.01%	179
2023 Q4	$42.7K	Buy	+13,246	New	+$45.3K	0.02%	120

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ADAR1 Capital Management's OVID Position: Q1 2026 in Review

ADAR1 Capital Management increased its Ovid Therapeutics (OVID) stake by 6% in Q1 2026, buying an estimated $463K and bringing the position to 4,544,113 shares worth $10.1M. The position accounts for 0.59% of the portfolio, ranked #45.

ADAR1 Capital Management first reported a position in OVID in Q4 2023 and has held it in 10 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

ADAR1 Capital Management held 4,544,113 shares of Ovid Therapeutics worth $10.1M as of Q1 2026.
ADAR1 Capital Management bought 259,113 Ovid Therapeutics shares in Q1 2026, an estimated $463K.
Ovid Therapeutics made up 0.59% of ADAR1 Capital Management's portfolio in Q1 2026, its #45 holding.
ADAR1 Capital Management first reported a position in Ovid Therapeutics in Q4 2023 and has held it in 10 quarters since.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.